Sanofi SA Inhaber EO 2

€ 68,52 <%= Resources.Global.txtDown %>

Opdateret 23-09-2016

I dag

Market closed

Marked er lukket, åbner klokken 09:00

	19 sep	Sanofi Files Suit in U.S. to Defend Paten Rights on Lantus® and Lantus® Solostar®

	16 sep	Sanofi: Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials

	15 sep	Sanofi: Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the ...

	13 sep	Sanofi's Fixed-Ratio Combination Helps More Patients Reach Mealtime Blood Sugar Target than Insulin Glargine Alone

	12 sep	Sanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform

	06 sep	Sanofi : Sanofi Board of Directors Provides Update

	06 sep	Sanofi successfully prices EUR 3 billion bond issue

	29 aug	Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

	23 aug	Sanofi : Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of th...

	19 aug	Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

Få fuld adgang til relaterede aktier på
Sanofi SA Inhaber EO 2
Klik her

For lav Flash Player version